Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.
暂无分享,去创建一个
B. Masquelier | F. Dabis | C. Rouzioux | M. Newell | D. Ekouevi | P. Perre | R. Thiébaut | E. Arrivé | V. Leroy | M. Chaix
[1] D. Richman,et al. 2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.
[2] Douglas G. Altman,et al. Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis , 2008 .
[3] S. Lagakos,et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. , 2007, The New England journal of medicine.
[4] D. Hoover,et al. Quantitative Analysis of HIV-1 Variants With the K103N Resistance Mutation After Single-Dose Nevirapine in Women With HIV-1 Subtypes A, C, and D , 2006, Journal of acquired immune deficiency syndromes.
[5] F. Dabis,et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. , 2006, The Journal of infectious diseases.
[6] B. Masquelier,et al. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission. , 2005, AIDS research and human retroviruses.
[7] D. Hoover,et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns , 2005, AIDS.
[8] D. Katzenstein,et al. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. , 2005, The Journal of infectious diseases.
[9] D. Hoover,et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. , 2005, The Journal of infectious diseases.
[10] D G Altman,et al. Indirect comparisons of competing interventions. , 2005, Health technology assessment.
[11] W. Heneine,et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. , 2005, The Journal of infectious diseases.
[12] Amalio Telenti,et al. Update of the Drug Resistance Mutations in HIV-1: 2005. , 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[13] B. G. Gutsche. Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy , 2005 .
[14] M. Wainberg,et al. HIV-1 subtype distribution and the problem of drug resistance , 2004, AIDS.
[15] Sujuan Gao. Combining binomial data using the logistic normal model , 2004 .
[16] P. Musoke,et al. Characterization of Nevirapine Resistance Mutations in Women With Subtype A Vs. D HIV-1 6–8 Weeks After Single-Dose Nevirapine (HIVNET 012) , 2004, Journal of acquired immune deficiency syndromes.
[17] John L Sullivan,et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. , 2003, The Journal of infectious diseases.
[18] R. Gelber,et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. , 2002, The Journal of infectious diseases.
[19] S. Thompson,et al. How should meta‐regression analyses be undertaken and interpreted? , 2002, Statistics in medicine.
[20] F. Dabis,et al. HIV-1/AIDS and maternal and child health in Africa , 2002, The Lancet.
[21] L. Mofenson,et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) , 2001, AIDS.
[22] L. Mofenson,et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission , 2000, AIDS.
[23] M. Fowler,et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. , 2000, JAMA.
[24] Dorothy Bray,et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.
[25] N. Rollins,et al. Surveillance of resistance in KZN South Africa, including mother-infant pairs 6 weeks after single-dose NVP , 2004 .
[26] S. Eshleman,et al. Nevirapine resistance after single dose prophylaxis. , 2002, AIDS reviews.
[27] Douglas G. Altman,et al. Systematic Reviews in Health Care , 2001 .